Effects of dichloroacetate on glycogen metabolism in B6C3F1 mice.
Dichloroacetate (DCA) is a by-product of drinking water chlorination. Administration of DCA in drinking water results in accumulation of glycogen in the liver of B6C3F1 mice. To investigate the processes affecting liver glycogen accumulation, male B6C3F1 mice were administered DCA in drinking water at levels varying from 0.1 to 3 g/l for up to 8 weeks. Liver glycogen synthase (GS) and glycogen phosphorylase (GP) activities, liver glycogen content, serum glucose and insulin levels were analyzed. To determine whether effects were primary or attributable to increased glycogen synthesis, some mice were fasted and administered a glucose challenge (20 min before sacrifice). DCA treatments in drinking water caused glycogen accumulation in a dose-dependent manner. The DCA treatment in drinking water suppressed the activity ratio of GS measured in mice sacrificed at 9:00 AM, but not at 3:00 AM. However, net glycogen synthesis after glucose challenge was increased with DCA treatments for 1-2 weeks duration, but the effect was no longer observed at 8 weeks. Degradation of glycogen by fasting decreased progressively as the treatment period was increased, and no longer occurred at 8 weeks. A shift of the liver glycogen-iodine spectrum from DCA-treated mice was observed relative to that of control mice, suggesting a change in the physical form of glycogen. These data suggest that DCA-induced glycogen accumulation at high doses is related to decreases in the degradation rate. When DCA was administered by single intraperitoneal (i.p.) injection to naïve mice at doses of 2-200 mg/kg at the time of glucose challenge, a biphasic response was observed. Doses of 10-25 mg/kg increased both plasma glucose and insulin concentrations. In contrast, very high i.p. doses of DCA (> 75 mg/kg) produced progressive decreases in serum glucose and glycogen deposition in the liver. Since the blood levels of DCA produced by these higher i.p. doses were significantly higher than observed with drinking water treatment, we conclude that apparent differences with data of previous investigations is related to substantial differences in systemic dose and/or dose-time relations.
Kato-Weinstein
J
J
Pharmacology/Toxicology Program, College of Pharmacy, Washington State University, Pullman 99164-6510, USA.
Lingohr
M K
MK
Orner
G A
GA
Thrall
B D
BD
Bull
R J
RJ
D000284:Administration, Oral; D000818:Animals; D001786:Blood Glucose; D003999:Dichloroacetic Acid / Q000097:blood / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D005215:Fasting; D005951:Glucose Tolerance Test; D006006:Glycogen Synthase / Q000378:metabolism; D007274:Injections, Intraperitoneal; D007328:Insulin / Q000097:blood; D008099:Liver / Q000187:drug effects* / Q000201:enzymology; D008112:Liver Glycogen / Q000302:isolation & purification / Q000378:metabolism*; D008297:Male; D051379:Mice; D006005:Phosphorylases / Q000378:metabolism
D001786:Blood Glucose; D007328:Insulin; D008112:Liver Glycogen; D003999:Dichloroacetic Acid; D006005:Phosphorylases; D006006:Glycogen Synthase